RadNet, Inc. Q2 FY2025 earnings call

Management Statement and Operational Highlights

• Business Rebound: After disruptions in Q1 due to wildfires and weather, Q2 saw record revenue and adjusted EBITDA. Industry trends, improved reimbursements, and focus on advanced imaging contributed to growth.
• Advanced Imaging Initiatives: TechLive remote screening technology expanded hours and capacity. Upgrades in MRI software reduced scan times, CT programs expanded complex procedures, and PET/CT emphasized new screenings for conditions like prostate cancer and Alzheimer's.
• Digital Health Developments: EBCD breast cancer screening program expanded, and acquisitions of iCAD and See-Mode Technologies were completed to enhance AI solutions and capacity.
• Financial Position: Cash balance was $833 million at quarter end, with net debt to adjusted EBITDA leverage slightly less than 1x.

Segment Performance

• Core Imaging Center: Total company revenue for Q2 2025 was $498.2 million, a 8.4% increase from Q2 2024. Advanced imaging procedures accounted for 27.5% of total procedures, up from 26.5% in Q2 2024. MRI saw 9% aggregate and 6.6% same-center growth, CT expanded complex procedures, and PET/CT increased 22.4% aggregate and 16.2% same-center.
• Digital Health: Revenue was $20.7 million, a 30.9% increase from Q2 2024. AI revenue grew 21.6%, and radiology software revenue grew 36.1%. Acquisitions of iCAD and See-Mode Technologies were completed to enhance AI solutions and capacity.

Guidance

• Imaging Center: Increased revenue and adjusted EBITDA guidance ranges, with a $15 million increase in revenue and $3 million in adjusted EBITDA. Capital expenditure guidance increased by $7 million.
• Digital Health: Guidance update planned for Q3, incorporating iCAD and See-Mode contributions.
• Medicare Reimbursement: Anticipated $4 million to $5 million benefit from 2026 physician fee schedule, after 5 years of cuts.

Risks

• Regulatory and Reimbursement Risks: Uncertainty in Medicare physician fee final rule and potential changes affecting reimbursement.
• Integration Risks: Challenges in integrating acquisitions like iCAD and ensuring smooth implementation of new technologies.
• Labor and Inflation Risks: Continued labor shortages and inflationary pressures impacting operations.

Question and Answer

Q: Can you give some sense of incremental capacity from TechLive and de novos?

A: Howard discussed reduced MRI room closures in NY and plan to open 9 de novo facilities by year-end, with 11 more in 2026.

Q: Initial feedback from iCAD customer base?

A: Howard mentioned early stages but pleased with sales and marketing team, expecting more details in Q3.

Q: Impact of Medicare physician fee schedule?

A: Mark explained need to analyze CPT codes and GPCIs, expecting $4-5M benefit but with mitigating factors.

Q: Utilization impact on capitated contracts?

A: Mark noted capitation business for 30 years, flipping some contracts to fee-for-service as reimbursement improves.

Q: DeepHealth implementation in centers?

A: Howard said centers use limited DeepHealth modules, with full implementation expected by end of 2026.